Phase Ib expansion and dose optimization study of CX-5461 in patients with solid tumours enriched for DNA-repair deficiencies.Ana Veneziani, AM Oza, Stephanie Lheureux et al.|Journal of Clinical Oncology|2026Cited by 0
A phase 1/2 study of EP0062 (vosilasarm), a first-in-class oral selective androgen receptor modulator (SARM), in combination with standard-of-care endocrine therapy +/- targeted therapies in patients with advanced or metastatic AR+/ER+/HER2− breast cancer.Rafael Grochot, J O'Shaughnessy, Rodrigo Sánchez-Bayona et al.|Journal of Clinical Oncology|2026Cited by 0